|Day Low/High||80.16 / 81.70|
|52 Wk Low/High||75.77 / 122.00|
Of the 57 index constituents, four Aristocrats have yields above 4.0%.
Jim Cramer says that if expectations are too high, even a great quarter cannot save you from the wave of selling.
Jim Cramer takes a look at Carvana, Bank OZK, Idexx Labs, Patterson-UTI Energy, 3D Systems, AbbVie and more.
- Milestone marks the 10th FDA approval for IMBRUVICA in six different disease areas since 2013
Stocks rose by Friday's close, getting a boost from a number of strong corporate earnings reports even as investors continue to worry about a lack of progress in U.S.-China trade talks.
The pharmaceutical company reports fourth-quarter results below analysts' consensus forecasts.
China's central bank announced a bill swap mechanism late Thursday aimed at slowing down the nation's economic slowdown.
- Reports Full-Year Diluted EPS of $3.66 on a GAAP Basis; Adjusted Diluted EPS of $7.91 Reflects Growth of 41.3 Percent
-- The RESOLVE (PCYC-1137) trial evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents
One of pharma's biggest CEO's talks M&A action on the exchange.
Jim Cramer talks about the Fed, and outlines your game plan.
Jim Cramer weighs in on Qualcomm, Momo, Ciena, AbbVie, LM Ericsson and more.
Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.
And it is happening not a moment too soon.
- Initiation of clinical studies with TTX-030 is targeted in Q1 2019
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
ABBV offers an ideal mix of growth, value and income.
- Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis[1-5]
As cannabis becomes more and more legal, investors have started to wonder what that means for them.
- Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped
- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)
- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment
- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients
- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.